Evidence map›Paper›PMID 35901087›Full record

ArticlePloS one2022

Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB).

Taylor D Ottesen, Blake N Shultz, Alana M Munger, Michael Amick, Courtney S Toombs, Gary E Friedaender, Jonathan N Grauer

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Chondrosarcoma: A Clinical Review.Journal of clinical medicine · 2023
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Taylor D OttesenDepartment of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, United States of America.ORCID 0000-0002-3777-1955
Blake N ShultzDepartment of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, United States of America.
Alana M MungerDepartment of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, United States of America.ORCID 0000-0002-3950-8923
Michael AmickDepartment of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, United States of America.
Courtney S ToombsDepartment of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, United States of America.
Gary E FriedaenderDepartment of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, United States of America.
Jonathan N GrauerDepartment of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, United States of America.ORCID 0000-0002-2626-7278

Funding

Short Term Research Training: Students in Health Professional SchoolsT35DK104689 · NIDDK · YALE UNIVERSITY · PI LLOYD G CANTLEY, Sarwat I Chaudhry · 2015 to 2026
$2.6M
6 · The paper itself

Abstract

introductionChondrosarcoma, although relatively uncommon, represents a significant percentage of primary osseous tumors. Nonetheless, there are few large-cohort, longitudinal studies of long-term survival and treatment outcomes of chondrosarcoma patients and none using the National Cancer Database (NCDB).

methodsChondrosarcoma patients were identified from the 2004-2015 NCDB datasets and divided on three primary tumor sites: appendicular, axial, and other. Demographic, treatment, and long-term survival data were determined for each group. Multivariate Cox analysis and Kaplan-Meier survival curves were generated to assess long-term survival over time for each.

resultsIn total, 5,329 chondrosarcoma patients were identified, of which 2,686 were appendicular and 1,616 were axial. Survival was higher among the appendicular cohort than axial at 1-year, 5-year, and 10-year (89.52%, 75.76%, and 65.24%, respectively). Multivariate Cox analysis identified patients in the appendicular cohort to have significantly greater likelihood of death with increasing age category, distant metastases at presentation, and male sex (p<0.001 for each). Best outcomes for seen for those undergoing surgical treatment (p<0.001). Patients in the axial cohort were with increased likelihood of death with increasing age category and distant metastases (p<0.001), while surgical treatment with or without radiation were associated with a significant decrease (p<0.001). Kaplan-Meier survival analysis showed worst survival for the axial cohort (p<0.001) and patients with distant metastases at presentation (p<0.001). Survival was not significantly different between older (2004-2007) and more recent years (2012-2016) (p = 0.742).

conclusionsFor both appendicular and axial chondrosarcomas, surgical treatment remains the mainstay of treatment due to its continued superiority for the long-term survival of patients, although advancements in survival over the last decade have been insignificant. Presence of distant metastases and axial involvement are significant, poor prognostic factors perhaps because of difficulty in surgical excision or extent of disease.

Indexed as

Bone NeoplasmsChondrosarcomaDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleTreatment Outcome

Identifiers

PMID35901087
PMCPMC9333210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.